BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32043598)

  • 1. Increased risk of dizziness in human immunodeficiency virus-infected patients taking zidovudine and efavirenz combination: a Brazilian cohort study.
    Valeriano JJLS; Carvalho-Silva WHV; Coelho AVC; Moura RR; Arraes LC; Brandão LAC; Crovella S; Guimarães RL
    J Pharm Pharmacol; 2020 May; 72(5):719-727. PubMed ID: 32043598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of Discontinuation of Efavirenz as Treatment for HIV, Due to Neuropsychiatric Side Effects, in a Multi-Ethnic Sample in the United Kingdom.
    Law JKC; Butler LT; Hamill MM
    AIDS Res Hum Retroviruses; 2020 Jun; 36(6):459-466. PubMed ID: 31931589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depression is associated with efavirenz-containing treatments in newly antiretroviral therapy initiated HIV patients in Ecuador.
    Checa A; Castillo A; Camacho M; Tapia W; Hernandez I; Teran E
    AIDS Res Ther; 2020 Jul; 17(1):47. PubMed ID: 32727488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline predictors of efavirenz-containing antiretroviral regimen adverse experiences.
    Sonenthal PD; Ratshaa B; Chimbengo G; Rantleru T; Ngoni T; Barenbaum S; Platoff R; Steenhoff AP; Gross R
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):773-7. PubMed ID: 24664872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse Neuropsychiatric Events and Recreational Use of Efavirenz and Other HIV-1 Antiretroviral Drugs.
    Dalwadi DA; Ozuna L; Harvey BH; Viljoen M; Schetz JA
    Pharmacol Rev; 2018 Jul; 70(3):684-711. PubMed ID: 29945900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transportability From Randomized Trials to Clinical Care: On Initial HIV Treatment With Efavirenz and Suicidal Thoughts or Behaviors.
    Mollan KR; Pence BW; Xu S; Edwards JK; Mathews WC; O'Cleirigh C; Crane HM; Eaton EF; Collier AC; Weideman AMK; Westreich D; Cole SR; Tierney C; Bengtson AM;
    Am J Epidemiol; 2021 Oct; 190(10):2075-2084. PubMed ID: 33972995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
    Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM
    N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: a 24-week prospective study.
    Jena A; Sachdeva RK; Sharma A; Wanchu A
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(5):318-22. PubMed ID: 19721097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events.
    Hoffmann CJ; Fielding KL; Charalambous S; Sulkowski MS; Innes C; Thio CL; Chaisson RE; Churchyard GJ; Grant AD
    AIDS; 2008 Jan; 22(1):67-74. PubMed ID: 18090393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher efavirenz plasma levels correlate with development of insomnia.
    Núñez M; González de Requena D; Gallego L; Jiménez-Nácher I; González-Lahoz J; Soriano V
    J Acquir Immune Defic Syndr; 2001 Dec; 28(4):399-400. PubMed ID: 11707679
    [No Abstract]   [Full Text] [Related]  

  • 11. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
    Gulick RM; Ribaudo HJ; Shikuma CM; Lustgarten S; Squires KE; Meyer WA; Acosta EP; Schackman BR; Pilcher CD; Murphy RL; Maher WE; Witt MD; Reichman RC; Snyder S; Klingman KL; Kuritzkes DR;
    N Engl J Med; 2004 Apr; 350(18):1850-61. PubMed ID: 15115831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maximizing Knowledge Extraction From Patient-Reported Outcome Data Using Exposure-Outcome Item Response Modeling Approach: Understanding Efavirenz-Induced Central Nervous System Toxicity.
    Bisaso KS; Bisaso KR; Mukonzo JK; Ette EI
    J Clin Pharmacol; 2020 Jun; 60(6):711-721. PubMed ID: 32096561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurotoxicities in the treatment of HIV between dolutegravir, rilpivirine and dolutegravir/rilpivirine: a meta-analysis.
    Allen Reeves A; Fuentes AV; Caballero J; Thomas JE; Mosley Ii JF; Harrington C
    Sex Transm Infect; 2021 Jun; 97(4):261-267. PubMed ID: 33782144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals.
    de Almeida TB; de Azevedo MCVM; Pinto JFDC; Ferry FRA; da Silva GAR; de Castro IJ; Baker P; Tanuri A; Haas DW; Cardoso CC
    J Antimicrob Chemother; 2018 Sep; 73(9):2460-2467. PubMed ID: 29868865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial.
    Gutiérrez-Valencia A; Viciana P; Palacios R; Ruiz-Valderas R; Lozano F; Terrón A; Rivero A; López-Cortés LF;
    Ann Intern Med; 2009 Aug; 151(3):149-56. PubMed ID: 19581631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.
    Ruane PJ; Parenti DM; Margolis DM; Shepp DH; Babinchak TJ; Van Kempen AS; Kauf TL; Danehower SA; Yau L; Hessenthaler SM; Goodwin D; Hernandez JE;
    HIV Clin Trials; 2003; 4(4):231-43. PubMed ID: 12916008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.
    Landovitz RJ; Angel JB; Hoffmann C; Horst H; Opravil M; Long J; Greaves W; Fätkenheuer G
    J Infect Dis; 2008 Oct; 198(8):1113-22. PubMed ID: 18783318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.
    Crespo M; Ribera E; Suárez-Lozano I; Domingo P; Pedrol E; López-Aldeguer J; Muñoz A; Viladés C; Sánchez T; Viciana P; Teira R; García-Alcalde ML; Vergara A; Lozano F; Galindo MJ; Cosin J; Roca B; Terrón A; Geijo P; Vidal F; Garrido M;
    J Antimicrob Chemother; 2009 Jan; 63(1):189-96. PubMed ID: 18988678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated to modification of first-line antiretroviral therapy due to adverse events in people living with HIV/AIDS.
    Azevedo LN; Ximenes RAA; Monteiro P; Montarroyos UR; Miranda-Filho DB
    Braz J Infect Dis; 2020; 24(1):65-72. PubMed ID: 31835018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria.
    Popoola TD; Awodele O; Oshikoya KA
    Afr J Med Med Sci; 2016 Jun; 45(2):179-187. PubMed ID: 29465861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.